Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

the prevalence of sight-threatening diabetic retinopathy was 3.6%, and the prevalence of mild retinopathy was 11.8%. • Floaters (spots or dark strings floating in your vision) • Dark or empty ...